Your browser doesn't support javascript.
loading
FOXO1 is a master regulator of memory programming in CAR T cells.
Doan, Alexander E; Mueller, Katherine P; Chen, Andy Y; Rouin, Geoffrey T; Chen, Yingshi; Daniel, Bence; Lattin, John; Markovska, Martina; Mozarsky, Brett; Arias-Umana, Jose; Hapke, Robert; Jung, In-Young; Wang, Alice; Xu, Peng; Klysz, Dorota; Zuern, Gabrielle; Bashti, Malek; Quinn, Patrick J; Miao, Zhuang; Sandor, Katalin; Zhang, Wenxi; Chen, Gregory M; Ryu, Faith; Logun, Meghan; Hall, Junior; Tan, Kai; Grupp, Stephan A; McClory, Susan E; Lareau, Caleb A; Fraietta, Joseph A; Sotillo, Elena; Satpathy, Ansuman T; Mackall, Crystal L; Weber, Evan W.
Afiliação
  • Doan AE; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Mueller KP; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Chen AY; Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Rouin GT; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Chen Y; Department of Pathology, Stanford University, Stanford, CA, USA.
  • Daniel B; Department of Bioengineering, Stanford University, Stanford, CA, USA.
  • Lattin J; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
  • Markovska M; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Mozarsky B; Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Arias-Umana J; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Hapke R; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Jung IY; Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Wang A; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Xu P; Department of Pathology, Stanford University, Stanford, CA, USA.
  • Klysz D; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
  • Zuern G; Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.
  • Bashti M; Department of Genetics, Stanford University, Stanford, CA, USA.
  • Quinn PJ; Genentech, South San Francisco, CA, USA.
  • Miao Z; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Sandor K; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Zhang W; Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Chen GM; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Ryu F; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Logun M; Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Hall J; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Tan K; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Grupp SA; Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • McClory SE; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Lareau CA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Fraietta JA; Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Sotillo E; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Satpathy AT; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Mackall CL; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Weber EW; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Nature ; 629(8010): 211-218, 2024 May.
Article em En | MEDLINE | ID: mdl-38600391
ABSTRACT
A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo1. The expression of memory-associated genes in CAR T cells is linked to their long-term persistence in patients and clinical efficacy2-6, suggesting that memory programs may underpin durable CAR T cell function. Here we show that the transcription factor FOXO1 is responsible for promoting memory and restraining exhaustion in human CAR T cells. Pharmacological inhibition or gene editing of endogenous FOXO1 diminished the expression of memory-associated genes, promoted an exhaustion-like phenotype and impaired the antitumour activity of CAR T cells. Overexpression of FOXO1 induced a gene-expression program consistent with T cell memory and increased chromatin accessibility at FOXO1-binding motifs. CAR T cells that overexpressed FOXO1 retained their function, memory potential and metabolic fitness in settings of chronic stimulation, and exhibited enhanced persistence and tumour control in vivo. By contrast, overexpression of TCF1 (encoded by TCF7) did not enforce canonical memory programs or enhance the potency of CAR T cells. Notably, FOXO1 activity correlated with positive clinical outcomes of patients treated with CAR T cells or tumour-infiltrating lymphocytes, underscoring the clinical relevance of FOXO1 in cancer immunotherapy. Our results show that overexpressing FOXO1 can increase the antitumour activity of human CAR T cells, and highlight memory reprogramming as a broadly applicable approach for optimizing therapeutic T cell states.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva / Proteína Forkhead Box O1 / Receptores de Antígenos Quiméricos / Memória Imunológica Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Imunoterapia Adotiva / Proteína Forkhead Box O1 / Receptores de Antígenos Quiméricos / Memória Imunológica Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article